DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0144997 A1 CHEN Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0144997 A1 CHEN Et Al US 201701.44997 A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0144997 A1 CHEN et al. (43) Pub. Date: May 25, 2017 (54) MODULATORS OF CHEMOKINE A6II 45/06 (2006.01) RECEPTORS C07D 405/2 (2006.01) A6II 3/4725 (2006.01) (71) Applicant: CHEMOCENTRYX, INC., Mountain A63L/455 (2006.01) View, CA (US) A6II 3/4439 (2006.01) C07D 209/246 (2006.01) (72) Inventors: Xi CHEN, E. Palo Alto, CA (US); A63L/506 (2006.01) Dean R. DRAGOLI, Los Altos, CA A63L/454 (2006.01) (US); Junfa FAN, Palo Alto, CA (US); C07D 307/52 (2006.01) Jaroslaw KALISAK, Mountain View, A63L/4035 (2006.01) CA (US); Antoni KRASINSKI, (52) U.S. C. Sunnyvale, CA (US); Manmohan CPC ......... C07D405/14 (2013.01); C07D 307/52 Reddy Leleti, San Jose, CA (US); (2013.01); A61 K3I/341 (2013.01); A61 K Venkat MALI, Cupertino, CA (US); 45/06 (2013.01); C07D405/12 (2013.01); Jeffrey McMAHON, San Francisco, A61K 31/4035 (2013.01); A61K 31/4155 CA (US); Rajinder SINGH, Belmont, (2013.01); A61 K3I/4439 (2013.01); C07D CA (US); Hiroko TANAKA, Mountain 209/46 (2013.01); A61 K3I/506 (2013.01); View, CA (US); Ju YANG, Palo Alto, A6 IK3I/454 (2013.01); A61K 31/4725 CA (US); Chao YU, Sunnyvale, CA (2013.01) (US); Penglie ZHANG, Foster City, CA (US) (57) ABSTRACT Compounds are provided as chemokine inhibitors having (21) Appl. No.: 15/353,889 the structure: (22) Filed: Nov. 17, 2016 Related U.S. Application Data R5a R55 O O R7 (60) Provisional application No. 62/257,389, filed on Nov. Xal \ 19, 2015, provisional application No. 62/277,711, R3. S. N N '' filed on Jan. 12, 2016. Rgb H H B pi Publication Classification R6a N O (51) Int. Cl. R4 CO7D 405/4 (2006.01) A6 IK3I/34 (2006.01) Patent Application Publication May 25, 2017. Sheet 1 of 38 US 2017/O144997 A1 FIGURE 1A CCR6 Cso CXCR2 Co O. O. N-2 N C- \ . --- OOO no o -- re re f\,-CO2H Nad O O C-Cya's N NSN 1.001 'n ŠO O5 X- es resea r t ; N-CO2H O-N O O C s y N. N. 1.002 N-so O2 ----- ------ --/f\,-CO2H O O Cl-, ---M Y s N Y OO3 SO o ------ ---- Patent Application Publication May 25, 2017. Sheet 2 of 38 US 2017/O144997 A1 FIGURE B CCR6 Cso CXCR2 Cso 1004 O2 ---- ----- \ face 1,005 d --- --- 006 --- 1.007 '. W 0.2 --- --- 1,008 |- --- --- d -- Patent Application Publication May 25, 2017. Sheet 4 of 38 US 2017/O144997 A1 FIGURE 1) CCR6 Co CXCR2 Cso O. O. s 1. Ni C/sC N ---- NN 014 (NSO d ----- ----- f; N-CO2h 's- Meo-Saj O O C/sy ---- l Aé-N N 1.05 N-so d ------ --- N--F N CO2H Ci?sy o, O Yi in Ns' \-i 1.016 N-so o re ter Meo-i(-)NF 101.7 is co-h --- --- Med-R- MeO O. O. 1.018 Y Oé ----- ----- Patent Application Publication May 25, 2017. Sheet 6 of 38 US 2017/O144997 A1 FIGURE F CCR6 Co CXCR2 Cso ci.sy Š-(? - i.- Aé's: N N & i-y N-so or --- --- 1.024 iš-CO2H o r -i.F f O O f Cl- is . 1,025 N SO o i N-CO2H N O C \-& N C/S Y A 2 1,026 ^ ------ Nrso! d (NCO2H N 1.027 ----- is-CO2Hf as N c A N N 'N 1.028 - - - -- N\COHso or Patent Application Publication May 25, 2017. Sheet 7 of 38 US 2017/O144997 A1 FIGURE 1G CCR6 IC50 CXCR2 Cso S 2-n" n O29 N SO d --- r \-ed O to C-?is2-N Nr. - 1.030 N-so? d)s ----- --- ) al -Co-H O O C. ^s ---- -- Aé-N N'S f N CO2H Fr. C. ^s O. o Yf Ala-N Nr y 1,032 N-so o --- ---- Chrf\,-CO2H c/s, O ... y y- N NS y n-s O% 1033 N-so --- --- f\,-CO2H Nal O Patent Application Publication May 25, 2017. Sheet 8 of 38 US 2017/O144997 A1 FIGURE 1H CCR6 Co CXCR2Cso C/s, A 2-N TN 1.034 - ----- --- f N-CO2H MeOS - O O \,-4% N Cls\ ---- +- 1.035 A?Niso N. N.OY ----- --- fN-CO2H - al o, O -\ \ Yi y --N No" - 1.036 , Niso, o s: es - O to Cl-k \ . - 1037 N- SO o H.-- --- f\,-CO2H- Y -s O. O.Y X- - N N Ni 1.038 N-so o ------ -- Patent Application Publication May 25, 2017. Sheet 9 of 38 US 2017/O144997 A1 FIGURE I CCR6 Cso CXCR2 Co O to O-SS - / SC N NS O39 N SO d S -CO2H -- O. O. % f -(f - 040 N SO d’s sess-r --- f\,-CO2H MeO-Self O to Yi /s - (y^-N : N ---- 1.041 N-Šs O OY ------ --- MeO-Redits co-h O. O. , sky - Y { /- N N \ - 1.042 N-so O% ------ --- Coo" 1,043 ------ --- Patent Application Publication May 25, 2017. Sheet 11 of 38 US 2017/0144997 A1 FIGURE 1 K CCR6 Cso CXCR2 Cso 1.049 N-so O --- --- A. Y OSO o d H- r O. O. F-y Š-1^N. A 2 N Nur 1.051 ANrso aY - ------ --- is-CO2H\-f O. O. F-A-,- -- A 's N T N \ 2-y. 1,052 so O- ----- --- frS-CO2H C N O O f F. \\ s r - y.a-. - N Nr.Ö 2 1053 N-so re --- &-COH Patent Application Publication May 25, 2017. Sheet 12 of 38 US 2017/O144997 A1 FIGURE L CCR6 Co CXCR2 Cso 1054 rare 1.055 re 1,056 ----- ---- 1.057 ------ 1.058 --- Patent Application Publication May 25, 2017. Sheet 13 of 38 US 2017/O144997 A1 FIGURE M. CCR6 Cso CXCR2 IC50 O. F^S FN Yi y - N N-- 059 K d2 ----- isNSo co-h s^ O \l- a 2-N N-- O60 NSO d ---- is co-h \-el O N^T N-- .06 N-S Oé ------ 1,062 Oé ----- vs. ----- Patent Application Publication May 25, 2017. Sheet 14 of 38 US 2017/O144997 A1 FIGURE 1N CCR6 Cso CXCR2 Co Cls, N-2. Yi A 2-N N- 2-y--- 1.064 N O o eas se f\, COOH C/s/s o :- o --- y 22-N - N Y. .065 N SO O ^ sess-r --- f N.-CO2H Nad O O ------ --- 1.066 1,067 ---- ------ 1,068 es ass Patent Application Publication May 25, 2017. Sheet 15 of 38 US 2017/0144997 A1 FIGURE O CCR6 Cso CXCR2 ICs O O Cl-, y - - y \r N N N. O69 N-so d as ev SNn O O ^s, N-Y f C/s NTt O70 N-so O4 -- SN Ns N N 1.07 ----- ----- 1.072 -- -- 1.073 ----- ----- Patent Application Publication May 25, 2017. Sheet 16 of 38 US 2017/0144997 A1 FIGURE 1P CCR6 Cso CXCR2 Co 1074 eas assa 1.075 N Yas Oé --- ear 1076 NSO o +--- --- 1.077 --- ear O O Cl-, f - 2 y -?-N / N' rev 1078 O N-so Oa --- Y-S N f Patent Application Publication May 25, 2017. Sheet 17 of 38 US 2017/O144997 A1 FIGURE i Q CCR6 Cso CXCR2 IC50 O O f Cls, ---- y A 2'-N N 1079 SO Oé’ --- sea HO-C-S- \ O. O. cus Š-6if Y 1,080 ----- --- -- HO-C-N O. O. Ci-s, Š-(?i. Y A 2'-N NS .08 po o ------ ------ CONH2 1,082 --- ----- o, to Cls. --- N-so O. A vs. ------ Patent Application Publication May 25, 2017. Sheet 18 of 38 US 2017/0144997 A1 FIGURE IR CCR6 Cso CXCR2 Cso O. O. , ^- N-- F ) is/ N irlfNN 1,084 N SO 2 - - --- -o N c/sy cP 9 Y| A 2-N N 1085 -- rer case { d 2 NSO O 2 N C-/s,A 2-N TN--- S- 1086 { N-so ds/ 2 ---- --- y N O. O N. & N } C/S -- 1087 N-S ".da ----- ------ f Y-Nd \ C/s ---- °l - 1.088 /C. - d) --- ----- Patent Application Publication May 25, 2017. Sheet 19 of 38 US 2017/0144997 A1 FIGURE IS CCR6 Cso CXCR2 Cso 1,089 sea- es O o Ni - C-x sy. ... N--f. 1.090 Nrso O. A re --- y H2NOC 109. -er ------ o o C -. ---- N Nut" y 1,092 -y O 22 ------ ------ CONH2o 1.093 --- Patent Application Publication May 25, 2017. Sheet 20 of 38 US 2017/O144997 A1 FIGURE T CCR6 Cso CXCR2Cso o o y C/s, n ... NNY. 1,094 N-so o --- Y co-h O. O. N. & N C. ^s Yi O95 re in .096 ------ --- Y.4% C-sA 2'-N i- Ne:Y 1097 N-so ".s ------ --- S HO2C O98 (se ----- Patent Application Publication May 25, 2017. Sheet 21 of 38 US 2017/0144997 A1 FIGURE 1U CCR6 Cso CXCR2 Cso O99 ev a 1100 - ----- 1.101 --- ----- O O C 102 --- re NSO N-W 103 N N e Patent Application Publication May 25, 2017. Sheet 22 of 38 US 2017/0144997 A1 FIGURE 1 V CCR6 IC50 CXCR2 ICs 1.104 sease -- a-- O. O cis N-% YN i AC 2-N N TNN ps-\ 105 N-so o -er r 1106 ----- --- 1107 ----- ----- 108 seats seats Patent Application Publication May 25, 2017. Sheet 23 of 38 US 2017/0144997 A1 FIGURE W CCR6 Co CXCR2 Cso 1.109 ----- -- a--- 1.10 e ------ 1.111 ----- ------ 1.112 ----- ------ O.
Load more

Recommended publications
  • Andrew Lai Thesis
    TOWARDS THE DEVELOPMENT OF NOVEL BISPECIFIC ANTIBODIES TO INHIBIT KEY CELL SURFACE RECEPTORS INTEGRAL FOR THE GROWTH AND MIGRATION OF TUMOUR CELLS Andrew Lai Bachelor of Science, UNSW 2008 Master of Biotechnology, QUT 2010 Bachelor of Applied Science (Hons), QUT 2012 Submitted for the degree of Doctor of Philosophy Institute of Health and Biomedical Innovation Faculty of Health Queensland University of Technology 2016 Keywords Breast cancer, extracellular matrix, insulin-like growth factor, metastasis, migration, therapeutics, phage display, single chain variable fragments, vitronectin Towards the development of novel bispecific antibodies to inhibit key cell surface receptors integral for the growth and migration of tumour cells i Abstract Metastatic breast cancer, or breast cancer which has spread from the primary tumour to distal secondary sites, remains a major killer of women today. Researchers have observed that the relationship between tumour cells and its surrounding environment plays an important role in cancer progression. One such interaction is between the Insulin-like growth factor (IGF) system and the integrin system, which has been demonstrated to be involved in cancer cell metabolic activity and migration. Therefore, the aim of this project was to translate this knowledge into the generation of bispecific antibody fragments (BsAb) targeting both systems, in order to disrupt their roles in cancer growth and metastasis. To screen for IGF-1R and αv integrin binding ScFv, a phage display enrichment procedure using the Tomlinson ScFv libraries was conducted. After the panning cycles, 192 clones were screened for binding using ELISA, of which 16 were selected for sequencing. Analysis of the results revealed 1 IGF-R and 3 αv integrin unique binding ScFv, which were all subsequently expressed in a bacterial expression system.
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Polmacoxib Item No. 17509 OO CAS Registry No.: 301692-76-2 Formal Name: 4-[3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl- S NH 4-oxo-2-furanyl]-benzenesulfonamide 2 MF: C H FNO S 18 16 4 O FW: 361.4 Purity: ≥98% F UV/Vis.: λmax: 238, 320 nm Supplied as: A crystalline solid O Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Polmacoxib is supplied as a crystalline solid. A stock solution may be made by dissolving the polmacoxib in the solvent of choice. Polmacoxib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of polmacoxib in ethanol is approximately 5 mg/ml and approximately 20 mg/ml in DMSO and DMF. Polmacoxib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, polmacoxib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Polmacoxib has a solubility of approximately 0.5 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Polmacoxib is an inhibitor of cyclooxygenase 2 (COX-2) and the carbonic anhydrase subtypes I (CAI) and 1 CAII. It inhibits COX-2 in the absence of carbonic anhydrase II with an IC50 value of 40 nM, which increases by approximately 4- and 17-fold in the presence of a CAII at a molar ratio of 1:1 and 1:5, respectively.2 It also inhibits CAI and CAII (IC50s = 210 and 95 nM, respectively).
    [Show full text]
  • Analgesic & Rheumatology
    Recommendations of the SEC (Analgesic & Rheumatology) made in its 72nd meeting held on 24.06.2021 & 25.06.2021 at CDSCO HQ New Delhi. File Name & Recommendations Agenda Drug Name, Firm Name No Strength New Drugs Division ND/MA/21/000076 M/s Hetero Labs Ltd. The firm presented their proposal of Polmacoxib 2 mg Fresh Application Phase III clinical trial protocol capsules along with BE study protocol before committee. After detailed deliberation, the 1. committee recommended for grant of permission to conduct the BE study. The firm should present the results of BE study before committee for further consideration of phase III clinical trial protocol. Biological Division BIO/CT- The firm presented their proposal 18/FF/2021/24609- for marketing authorization and Belimumab (Marketing Authorization)- local clinical trial waiver based on Belimumab the results of GCT including sub set analysis on 66 Indian patients. The committee noted that the drug is not an unmet need in the country. M/s. GSK Further, the data presented by the 2. Pharmaceuticals firm in Indian sub-set is limited and Ltd. in different route of administration (intravenous) while the firm is seeking MA for subcutaneous route. After detailed deliberation, the committee did not recommend for grant of approval for marketing authorization. BIO/CT21/FF/2021/246 M/s Reliance Life The firm presented their proposal 79- Denosumab Sciences Pvt ltd for marketing authorization along 60mg/ml with the results of Phase-III clinical trial. 3. The committee noted that the Phase III trial was approved
    [Show full text]
  • The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives
    cancers Review The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives Pierluigi Scalia 1,2,*, Antonio Giordano 1,3 and Stephen J. Williams 1,4 1 Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Biology Department, Temple University, Philadelphia, PA 19122, USA; [email protected] (A.G.); [email protected] (S.J.W.) 2 Istituto Somatogene per la Ricerca Onco-Genomica, ISOPROG, 93100 Caltanissetta, Italy 3 Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy 4 Somatolink Foundation, Inc., Philadelphia, PA 19102, USA * Correspondence: [email protected] Received: 31 December 2019; Accepted: 2 February 2020; Published: 5 February 2020 Abstract: Insulin receptor overexpression is a common event in human cancer. Its overexpression is associated with a relative increase in the expression of its isoform A (IRA), a shorter variant lacking 11 aa in the extracellular domain, conferring high affinity for the binding of IGF-II along with added intracellular signaling specificity for this ligand. Since IGF-II is secreted by the vast majority of malignant solid cancers, where it establishes autocrine stimuli, the co-expression of IGF-II and IRA in cancer provides specific advantages such as apoptosis escape, growth, and proliferation to those cancers bearing such a co-expression pattern. However, little is known about the exact role of this autocrine ligand–receptor system in sustaining cancer malignant features such as angiogenesis, invasion, and metastasis. The recent finding that the overexpression of angiogenic receptor kinase EphB4 along with VEGF-A is tightly dependent on the IGF-II/IRA autocrine system independently of IGFIR provided new perspectives for all malignant IGF2omas (those aggressive solid cancers secreting IGF-II).
    [Show full text]
  • Concomitant Use of Nsaids Or Ssris with Noacs Requires Monitoring for Bleeding
    Original Article Yonsei Med J 2020 Sep;61(9):741-749 https://doi.org/10.3349/ymj.2020.61.9.741 pISSN: 0513-5796 · eISSN: 1976-2437 Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding Min-Taek Lee1, Kwang-Yeol Park2, Myo-Song Kim1, Seung-Hun You1, Ye-Jin Kang1, and Sun-Young Jung1 1College of Pharmacy, Chung-Ang University, Seoul; 2Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. Purpose: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in patients with atrial fibrillation (AF) because of their effectiveness in preventing stroke and their better safety, compared with warfarin. However, there are concerns for an in- creased risk of bleeding associated with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) or selective sero- tonin reuptake inhibitors (SSRIs) with NOACs. In this study, we aimed to evaluate the risk of bleeding events in individuals taking concomitant NSAIDs or SSRIs with NOACs after being diagnosed with AF. Materials and Methods: A nested case-control analysis to assess the safety of NSAIDs and SSRIs among NOAC users with AF was performed using data from Korean National Health Insurance Service from January 2012 to December 2017. Among patients who were newly prescribed NOACs, 1233 cases hospitalized for bleeding events were selected, and 24660 controls were determined. Results: The risk of bleeding events was higher in patients receiving concomitant NSAIDs [adjusted odds ratio (aOR) 1.41; 95% confidence interval (CI) 1.24–1.61] or SSRIs (aOR 1.92; 95% CI 1.52–2.42) with NOACs, compared to no use of either drug, respec- tively.
    [Show full text]
  • Directory of Korean Pharmaceutical Industry 2016
    2016 Directory of Korean Pharmaceutical Industry Contents 1. Greeting ������������������������������������������������������������������������������������������������������������������������������������������� 4 2. Overview of the Korean Pharmaceutical Industry ������������������������������������������������������������ 6 1) Current Status 2) Production Management System 3) Development of New Drugs 4) R&D Reinforcement 5) Biopharmaceuticals 6) Globalization 7) Korean Pharmaceutical Industry Vision - PHARMA 2020 3. Directory of Pharmaceutical Companies �������������������������������������������������������������������������� 13 · Regular Members(2015. 4) A~D ���������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 14 E~J ��������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 66 K~P �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 110 R~Y �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 158 · Associated Members(2015. 4) C~G ���������������������������������������������������������������������������������������������������������������������������������������������������������������������������
    [Show full text]
  • “M/S. AJANTA PHARMA LTD.”
    APPLICATION FOR ENVIRONMENTAL CLEARANCE OF PROPOSED EXPANSION OF ACTIVE PHARMACEUTICAL INGREDIENTS (API), MANUFACTURING UNIT “M/s. AJANTA PHARMA LTD.” 11KM Stone, Gut No. 378, Plot No 8, Aurangabad –Pune Highway, Village-Waluj, Taluka. Gangapur, District. Aurangabad- 431133. FORM 1 Submitted to Expert Appraisal Committee (Industry-2), MoEFCC, New Delhi Submitted by M/s. AJANTA PHARMA LTD. Environmental Consultant: Building Environment (India) Pvt. Ltd Dakshina Building, Office No. 401, Plot No. 2, Sector-11, CBD Belapur, Navi Mumbai- 400 614 January, 2018. Form 1 for proposed Expansion of API Manufacturing Industry “M/s. Ajanta Pharma Ltd.” at Waluj Village, Taluka-Gangapur, District- Aurangabad, Maharashtra. Form – 1 (I) Basic Information:- Sr. Items Details No. 1. Name of the project Proposed expansion of Active Pharmaceutical Ingredients (API) Manufacturing Industry “M/s. Ajanta Pharma Ltd.” 2. S. No. in the schedule Category 5f as per EIA Notification 2006 & amendments 3. Proposed capacity/ area/ length/ Industry is already engaged in manufacturing 85 nos. of tonnage to be handled/ command API and having production capacity 21.042 MT/Month. area/lease area/ number of wells to In the proposed expansion industry will manufacture 256 be drilled nos. API including existing API. The total production capacity after expansion would remain same as existing i.e. 21.042 MT/Month. Annexure-1 : Details of existing & proposed API 4. New / Expansion / Modernization Expansion. Annexure -2: EC letter of existing unit 5. Existing Capacity/ Area etc. Industry is already engaged in manufacturing 85 nos. of API and having production 21.042 MT/Month. Annexure-3 : Details of existing API 6.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]